FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079718824> ?p ?o ?g. }

• W2079718824 endingPage "271" @default.
• W2079718824 startingPage "260" @default.
• W2079718824 abstract "The primary objective of this study was to assess the efficacy and tolerability of tapentadol immediate release (IR) in patients who were candidates for joint replacement surgery due to end-stage joint disease. A secondary objective was to compare tapentadol IR with oxycodone HCl IR with respect to efficacy and prespecified tolerability end points.This 10-day, Phase III, randomized, double-blind, active- and placebo-controlled study compared the efficacy and tolerability of tapentadol IR, oxycodone HCl IR, and placebo in patients with uncontrolled osteoarthritis pain who were candidates for primary replacement of the hip or knee as a result of end-stage degenerative joint disease. Patients received tapentadol IR 50 mg, tapentadol IR 75 mg, oxycodone HCl IR 10 mg, or placebo every 4 to 6 hours during waking hours. The primary end point was the sum of pain intensity difference (SPID) over 5 days. Secondary efficacy end points included 2- and 10-day SPID; 2-, 5-, and 10-day total pain relief (TOTPAR); and the sum of total pain relief and pain intensity difference (SPRID). Prespecified noninferiority comparisons with oxycodone HCl IR were performed with respect to efficacy (based on 5-day SPID) and tolerability (based on incidence of the reported adverse events (AEs) of nausea and/or vomiting and constipation).Of 666 patients originally enrolled, 659 were included in the efficacy analysis (51% male; 91% white; mean age, 61.2 years; mean weight, 97 kg). Five-day SPID was significantly lower in those treated with tapentadol IR (tapentadol IR 50 mg: least squares mean difference [LSMD] = 101.2 [95% CI, 54.58- 147.89]; tapentadol IR 75 mg: LSMD = 97.5 [95% CI, 51.81-143.26]) or oxycodone HCl IR (LSMD = 111.9 [95% CI, 66.49-157.38]) (all, P < 0.001). Tapentadol IR 50 and 75 mg and oxycodone HCl IR 10 mg were associated with significant reductions in pain intensity compared with placebo, based on 2- and 10-day SPID and 2-, 5-, and 10-day TOTPAR and SPRID (all, P < 0.001). The efficacy of tapentadol IR 50 and 75 mg was noninferior to that of oxycodone HCl IR 10 mg; however, the incidence of selected gastrointestinal AEs (nausea, vomiting, and constipation) was significantly lower for both doses of tapentadol IR compared with oxycodone HCl IR 10 mg (nominal P < 0.001). The odds ratios for nausea and/or vomiting for tapentadol IR 50 and 75 mg relative to oxycodone HCl IR 10 mg were 0.21 (95% CI, 0.128-0.339) and 0.32 (95% CI, 0.204-0.501), respectively; for constipation, the corresponding odds ratios were 0.13 (95% CI, 0.057-0.302) and 0.20 (95% CI, 0.098-0.398). Rates of treatment discontinuation were 18% (28/157) in the tapentadol IR 50-mg group, 26% (43/168) in the tapentadol IR 75-mg group, 35% (60/172) in the oxycodone HCl IR 10-mg group, and 10% (17/169) in the placebo group. In a post hoc analysis, tapentadol IR 50 mg was associated with a significantly lower incidence of treatment discontinuation than was oxycodone HCl IR 10 mg (P < 0.001).In these patients with uncontrolled osteoarthritis pain who were awaiting joint replacement surgery, tapentadol IR 50 and 75 mg were associated with analgesia that was noninferior to that provided by oxycodone HCl IR 10 mg. Tapentadol treatment was associated with improved gastrointestinal tolerability." @default.
• W2079718824 created "2016-06-24" @default.
• W2079718824 creator A5007370082 @default.
• W2079718824 creator A5035606670 @default.
• W2079718824 creator A5070207046 @default.
• W2079718824 creator A5084091819 @default.
• W2079718824 creator A5087829561 @default.
• W2079718824 date "2009-02-01" @default.
• W2079718824 modified "2023-09-23" @default.
• W2079718824 title "Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, double-blind, active- and placebo-controlled study" @default.
• W2079718824 cites W142954314 @default.
• W2079718824 cites W1985118454 @default.
• W2079718824 cites W1989913047 @default.
• W2079718824 cites W2020387702 @default.
• W2079718824 cites W2035397928 @default.
• W2079718824 cites W2048164399 @default.
• W2079718824 cites W2049819003 @default.
• W2079718824 cites W2051746492 @default.
• W2079718824 cites W2084610846 @default.
• W2079718824 cites W2115805053 @default.
• W2079718824 cites W2124232531 @default.
• W2079718824 cites W2132309748 @default.
• W2079718824 cites W2157999436 @default.
• W2079718824 cites W2162051366 @default.
• W2079718824 cites W2167931192 @default.
• W2079718824 cites W2330813625 @default.
• W2079718824 cites W2610860323 @default.
• W2079718824 cites W3194956376 @default.
• W2079718824 cites W4247185122 @default.
• W2079718824 doi "https://doi.org/10.1016/j.clinthera.2009.02.009" @default.
• W2079718824 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19302899" @default.
• W2079718824 hasPublicationYear "2009" @default.
• W2079718824 type Work @default.
• W2079718824 sameAs 2079718824 @default.
• W2079718824 citedByCount "162" @default.
• W2079718824 countsByYear W20797188242012 @default.
• W2079718824 countsByYear W20797188242013 @default.
• W2079718824 countsByYear W20797188242014 @default.
• W2079718824 countsByYear W20797188242015 @default.
• W2079718824 countsByYear W20797188242016 @default.
• W2079718824 countsByYear W20797188242017 @default.
• W2079718824 countsByYear W20797188242018 @default.
• W2079718824 countsByYear W20797188242019 @default.
• W2079718824 countsByYear W20797188242020 @default.
• W2079718824 countsByYear W20797188242021 @default.
• W2079718824 countsByYear W20797188242022 @default.
• W2079718824 countsByYear W20797188242023 @default.
• W2079718824 crossrefType "journal-article" @default.
• W2079718824 hasAuthorship W2079718824A5007370082 @default.
• W2079718824 hasAuthorship W2079718824A5035606670 @default.
• W2079718824 hasAuthorship W2079718824A5070207046 @default.
• W2079718824 hasAuthorship W2079718824A5084091819 @default.
• W2079718824 hasAuthorship W2079718824A5087829561 @default.
• W2079718824 hasConcept C126322002 @default.
• W2079718824 hasConcept C141071460 @default.
• W2079718824 hasConcept C142724271 @default.
• W2079718824 hasConcept C168563851 @default.
• W2079718824 hasConcept C170493617 @default.
• W2079718824 hasConcept C197934379 @default.
• W2079718824 hasConcept C203092338 @default.
• W2079718824 hasConcept C204787440 @default.
• W2079718824 hasConcept C27081682 @default.
• W2079718824 hasConcept C2776029756 @default.
• W2079718824 hasConcept C2778375690 @default.
• W2079718824 hasConcept C2780505013 @default.
• W2079718824 hasConcept C2780580376 @default.
• W2079718824 hasConcept C2781063702 @default.
• W2079718824 hasConcept C42219234 @default.
• W2079718824 hasConcept C71924100 @default.
• W2079718824 hasConceptScore W2079718824C126322002 @default.
• W2079718824 hasConceptScore W2079718824C141071460 @default.
• W2079718824 hasConceptScore W2079718824C142724271 @default.
• W2079718824 hasConceptScore W2079718824C168563851 @default.
• W2079718824 hasConceptScore W2079718824C170493617 @default.
• W2079718824 hasConceptScore W2079718824C197934379 @default.
• W2079718824 hasConceptScore W2079718824C203092338 @default.
• W2079718824 hasConceptScore W2079718824C204787440 @default.
• W2079718824 hasConceptScore W2079718824C27081682 @default.
• W2079718824 hasConceptScore W2079718824C2776029756 @default.
• W2079718824 hasConceptScore W2079718824C2778375690 @default.
• W2079718824 hasConceptScore W2079718824C2780505013 @default.
• W2079718824 hasConceptScore W2079718824C2780580376 @default.
• W2079718824 hasConceptScore W2079718824C2781063702 @default.
• W2079718824 hasConceptScore W2079718824C42219234 @default.
• W2079718824 hasConceptScore W2079718824C71924100 @default.
• W2079718824 hasIssue "2" @default.
• W2079718824 hasLocation W20797188241 @default.
• W2079718824 hasLocation W20797188242 @default.
• W2079718824 hasOpenAccess W2079718824 @default.
• W2079718824 hasPrimaryLocation W20797188241 @default.
• W2079718824 hasRelatedWork W1562338169 @default.
• W2079718824 hasRelatedWork W1960545086 @default.
• W2079718824 hasRelatedWork W2079718824 @default.
• W2079718824 hasRelatedWork W2086444128 @default.
• W2079718824 hasRelatedWork W2102225351 @default.
• W2079718824 hasRelatedWork W2138106505 @default.
• W2079718824 hasRelatedWork W3172359983 @default.
• W2079718824 hasRelatedWork W3212096909 @default.

• next